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The need for reliable serum 
parathyroid hormone 
measurements
P Ureña Torres1
Serum parathyroid hormone (PTH) is a recognized marker of 
bone remodeling in patients with renal osteodystrophy. However,  
identification of N-terminal truncated PTH fragments and a new form 
of PTH that interfere with second-generation PTH assays  may be 
responsible for the great variability of  PTH values and the difficulties 
of implementing the recommendations of the National Kidney 
Foundation/Kidney Disease Outcomes Quality Initiative.
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Parathyroid hormone (PTH) is a polypep-
tide molecule of 84 amino acids with a 
molecular weight of 9500 daltons. It is 
synthesized by and secreted from the 
chief epithelial cells of parathyroid glands. 
sor molecule called pre-pro-PTH, which 
is encoded by a single gene located on the 
short arm of chromosome 11 (11p15). 
Th is gene has three exons separated by two 
introns; the fi rst exon contains most of the 
5′ non-coding region of the gene, and the 
second exon codes for most of the pre-pro-
PTH sequence. Th e third exon codes for 
three regions: the cleavage site Lys-Arg, 
the mature 1–84 PTH sequence, and the 
untranslated 3′ region.3 Th e mature PTH is 
stocked in secretory granules that fuse with 
the cellular membrane and release PTH in 
response to reduction in the extracellular 
ionized-calcium concentration. Most of 
this PTH is secreted in its intact form, 
1–84; however, it can also be secreted as 
N-terminal truncated fragments or C-ter-
minal fragments aft er intracellular degra-
dation, as in case of hypercalcemia.4 No 
PTH fragment has been found to be the 
result of another gene or alternative splic-
ing of the PTH gene.
Normally, on the basis of the percent-
age of the total immunoreactivity detected 
by diff erent PTH assays, sometimes vali-
dated by the evaluation of PTH molecu-
lar-form concentrations derived from 
high-performance liquid chromatogra-
phy profi les,4 approximately 10%–20% of 
the total circulating PTH molecules are 
in its intact and bioactive form (1–84) 
(Table 1). Indeed, once the secreted 1–84 
PTH reaches the circulation, it is rapidly 
taken up by the liver and the kidney and 
metabolized by several endoproteases in 
two main fragments: N-terminal and C-
terminal fragments (the half-life of the 
entire molecule varies between 2 and 
5 minutes). In the liver, all intact and N-
terminal fragments are metabolized, and 
no N-terminal fragment is released. Th is 
degradation gives rise to several C-termi-
nal fragments, starting from residues at 
positions 34, 37, 41, and 43 and ending 
probably at position 84 or shorter, which 
are oft en released back into the circula-
tion.5,6 Quantitatively, less than 20% of the 
intact PTH is converted into C-terminal 
fragments by the liver. However, because 
of their longer half-life (fi ve to ten times 
longer than that of the intact form) and 
because they are normally cleared by the 
kidneys, those C-terminal PTH frag-
ments represent 80% of the total circulat-
ing PTH molecules in normal individuals 
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Developmentally, there are four orthotopic 
parathyroid glands derived from the pha-
ryngeal pouch; however, supernumerary, 
scanty, and/or ectopic parathyroid glands 
can be seen in a small percentage of sub-
jects.1 Th e formation of these glands is 
under the control of a key regulatory gene 
coding for the transcription factor Gcm-2 
(glial cell missing), which is almost exclu-
sively expressed in these cells.2 PTH is 
synthesized as a 115-amino acid precur-
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(Table 1). Th e kidney is the second organ 
where PTH is catabolized. Aft er crossing 
the glomerular fi ltration membrane, all 
PTH molecules are actively reabsorbed 
by the proximal tubular cells through two 
mechanisms: binding to its specifi c recep-
tor (PTHR1) and internalization through 
the megalin/cubulin endocytosis system.7 
Th us, no detectable PTH fragments can be 
found in the fi nal urine.
Because the kidneys play an impor-
tant role in the catabolism of intact PTH 
and also of its fragments, when they fail, 
there is a tendency toward the accumu-
lation of circulating PTH fragments. 
However, this accumulation seems to be 
disproportionate to the degree of renal 
insuffi  ciency and could be the result of 
two phenomena: the renal clearance of 
C-terminal fragments is sensibly lower 
than that of intact 1–84 PTH, and sec-
ondly, it is now recognized that parathy-
roid glands can also release C-terminal 
fragments, namely 7–84 PTH,6 thereby 
increasing further the burden of these 
fragments. Th e skeletal tissue is another 
organ that can also clear a small frac-
tion of circulating intact PTH molecules 
though a receptor-mediated process.8
Chronic kidney disease is oft en associ-
ated with skeletal and mineral disorders 
globally described as renal osteodystro-
phy (ROD), ranging from high-turnover 
bone diseases such as secondary hyper-
parathyroidism, with its extreme and 
severe manifestation osteitis fi brosa, to 
low-turnover bone diseases such as osteo-
malacia and adynamic bone disease.9 
Th e gold-standard method to make the 
diagnosis of the type of ROD is still the 
histomorphometric analysis of iliac crest 
bone biopsies obtained aft er double tetra-
cycline labeling.9 However, this invasive 
and complicated method cannot be used 
in daily practice, so alternative methods 
must be used. Because the circulating con-
centration of PTH is well correlated with 
the degree of bone turnover, it has been 
largely used as a surrogate of bone biopsy, 
and nephrologists have been searching 
for decades for a better and more reliable 
method to measure it.
Th e fi rst generation of PTH assays were 
developed and used from 1959 to 1987. 
They used a single antibody directed 
against PTH (epitopes on amino acids 
39–84 or 53–84) in the radioimmunoassay 
and measured many blood-borne frag-
ments of PTH along with 1–84 PTH.10 
Th e second-generation PTH assays, called 
‘intact’ PTH assays, have been devel-
oped since 1987.11 Th ey use two diff er-
ent antibodies; the fi rst, directed against 
the C-terminal region of PTH (epitopes 
on amino acids 39–84, 44–84, 55–64, or 
53–84), is oft en immobilized onto plastic 
surfaces and binds intact 1–84 PTH and 
C-terminal PTH fragments. Th e second 
antibody is directed against the N-termi-
nal region (epitopes on amino acids 13–
34, the ‘proximal epitope,’ as in the Allegro 
assay from Nichols Institute Diagnostics; 
or 26–32, the ‘distal epitope,’ as in the 
Elecsys assay from Roche Diagnostics), 
and it is oft en radiolabeled, biotinylated, 
bound to an enzyme to allow its easy 
detection and quantifi cation, or served 
as the coated antibody. Th ese ‘sandwich’ 
assays were the fi rst radioimmunometric 
assays, and they were thought to measure 
only the full-length 1–84 PTH; however, 
they also measure large PTH fragments 
(namely 7–84 PTH).12 Th ese N-termi-
nal truncated PTH fragments have now 
been demonstrated to inhibit the action of 
PTH by blocking its binding to its normal 
receptor, PTHR1. Th ey may also bind to 
a specifi c C-terminal PTH receptor and 
may have multiple not-yet-known bio-
logical functions in the skin, bone, hemat-
opoietic system, and placenta.6,13,14 Th e 
third generation of PTH assays have been 
developed since 2000; they use the same 
sandwich and radioimmunometric tech-
niques, with the fi rst antibody directed 
against amino acids 39–84, but the second 
antibody has been restricted and directed 
against the fi rst six N-terminal residues of 
1–84 PTH (epitopes on amino acids 1–4 
or 1–5). Th ey have been demonstrated to 
be most sensitive, and more specifi c, when 
measuring bioactive intact 1–84 PTH, 
and probably another new form of PTH 
named amino-PTH, recently identifi ed in 
patients with parathyroid carcinoma and 
with severe cases of primary and second-
ary hyperparathyroidism.15
From the beginning, the utility of the 
third-generation PTH assays has gen-
erated a highly charged debate. And it 
should be emphasized here that the eco-
nomic stakes of this debate should lead 
clinicians to assess all claims carefully. 
Many of the studies published found an 
excellent correlation of serum PTH values 
between the second- and third-generation 
PTH assays16–18 in chronic kidney dis-
ease patients undergoing dialysis. How-
ever, mean circulating PTH levels are 
30%–60% lower with the third-generation 
PTH assays than with the second-genera-
tion assays. Furthermore, most uremic 
patients exhibit a normal ratio of intact 
to N-terminal truncated PTH fragments 
(intact PTH/N-terminal truncated PTH 
– intact PTH); however, in certain cases, 
this ratio can be abnormal, which has led 
several investigators to propose that a 
ratio lower than 1 could be the best pre-
dictor of a low bone-turnover disease.19 
Other investigators have been unable to 
confi rm these fi ndings.20
Souberbielle et al.21 (this issue) have 
elegantly looked at the inter-method 
variability in the measurement of circu-
lating PTH concentration of 15 diff erent 
PTH assays (13 second-generation and 
two third-generation PTH assays) in 47 
Table 1 | Approximate estimation of the percentage of the total immunoreactivity 
detected by three different parathyroid hormone (PTH) assays, before and after 
validation by the evaluation of PTH molecular-form concentrations derived from 
high-performance liquid chromatography profiles4,15
Intact 1–84 PTH
(%)
C-terminal PTH fragments
(%)
Normal subjects 20 80
14.0 of intact 1–84 PTH, 4.4 
of N-terminal truncated 
PTH, 1.6 of amino-PTH
Chronic renal failure 5 95
2.5 of intact 1–84 PTH, 1.8 of 
N-terminal truncated PTH, 
0.7 of amino-PTH
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pools of serum samples from a French 
population of dialyzed patients. Th ey also 
looked at the recovery of graded amounts 
of synthetic full-length 1–84 PTH and 
N-terminal truncated 7–84 PTH added 
separately to a normal serum pool. Th ey 
demonstrate that, when the second-gen-
eration Allegro intact PTH assay (Nichols 
Institute Diagnostics) was used as the ref-
erence assay, the median bias between the 
diff erent PTH assays varied from –44.9% 
to +123.0% (Figure 1). Th is implies that 
we may be under- or overestimating the 
true serum PTH concentration depending 
on the type of PTH assay we have cho-
sen. A patient with a serum PTH value of 
150 pg/ml or 300 pg/ml in one place may 
have values between 83 and 323 pg/ml 
and between 160 and 638 pg/ml, respec-
tively, in another place.
Th is clearly illustrates that the method 
used to measure circulating PTH con-
centration is a very important clinical, 
economic, and ethical issue. The most 
striking example is that one would never 
indicate a surgical parathyroidectomy or 
start aggressively and expensively to treat 
secondary hyperparathyroidism in a 
patient with serum PTH levels lower than 
300 pg/ml, unless the laboratory inaccu-
rately reported a value above 600 pg/ml 
because of the use of an unreliable method. 
Indeed, this variability in the PTH meas-
urement may explain the drift  and rise in 
the incidence of surgical parathyroidec-
tomy in the United States between 1998 
and 2002.22 At that time, Nichols Institute 
intended to replace the second-generation 
Allegro intact PTH assay with the auto-
mated Intact PTH Advantage, already 
introduced in the market in 1992; how-
ever, it was not well calibrated or shift ed 
upward such that it gave greater values for 
serum PTH concentration. Th e economic 
impact is huge, not only because we might 
be overtreating our patients with expen-
sive drugs, but also because the frequency 
of PTH determinations in uremic patients 
has dramatically increased during the last 
7 years, mainly because of the need for a 
closer monitoring of serum PTH levels 
in patients treated by calcimimetics, and 
because of the recommendations given 
by the Kidney Disease Outcomes Quality 
Initiative of the National Kidney Foun-
dation (NKF/K-DOQI) since 1998. Th us, 
this market has exploded and can be easily 
estimated to exceed several hundred mil-
lion dollars per year worldwide. It appears 
unethical that all the companies making 
diff erent PTH assays could not meet and 
decide how to standardize and calibrate a 
consistent circulating PTH measurement. 
Many physicians are making huge eff orts 
to keep their patients within the target val-
ues recommended by the NKF/K-DOQI; 
however, most of them are misinformed 
by their PTH measurement.
It should also be stressed here that the 
bone response to a given circulating PTH 
concentration in uremic patients is very 
variable; it depends on the level of PTH 
receptor expression and function,23,24 
and/or on the existence of a specifi c C-
terminal PTH receptor.6 For the moment, 
this variability limits any attempt to pre-
dict the type of ROD with only the meas-
urement of whatever type of PTH assay 
— intact, N-terminal truncated PTH 
fragments or C-terminal PTH fragments. 
However, as these naturally occurring 
PTH fragments may also exhibit biologi-
cal actions, it is quite conceivable that in 
the future their independent measure-
ment may increase the diagnostic sensi-
tivity of the type of ROD.
Th e most appropriate strategy would be 
to combine these PTH measurements with 
specifi c biochemical markers of bone for-
mation rate — such as bone-specifi c alka-
line phosphatase — and of bone resorption 
rate — such as collagen type I breakdown 
cross-linked peptides (cross-laps) — in 
order to gather more information about 
the bone response to a given serum PTH 
concentration.25,26 Th e combination of 
these measures might improve the pre-
diction of the type of ROD. However, this 
kind of study remains to be performed.
Finally, until there is a generalized use 
of a unique, true, and accurate intact 
1–84 PTH assay, it would be worthwhile 
for current PTH assays to be calibrated 
against a validated international standard 
of synthetic or recombinant 1–84 PTH. 
Furthermore, it is the responsibility of 
all companies fabricating second-gen-
eration PTH assays to provide a way to 
correct all results obtained. Th ese val-
ues could be corrected, as proposed by 
Souberbielle et al.,21 by a specifi c factor 
such as the inverse of the slope reported 
in Table 2 of their article, or the inverse of 
the bias presented in Table 3 of their arti-
cle. Ultimately, even if these measures are 
taken, it will be necessary to re-evaluate 
the impact of new intact 1–84 PTH values 
on the NKF/K-DOQI recommendations 
and on the morbidity and mortality risks 
associated with high serum intact PTH 
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Figure 1 | Variability of serum parathyroid hormone (PTH) concentration with second- and 
third-generation PTH assays. From results of Table 3 of the article by Souberbielle et al.21 (this 
issue). DSL, Diagnostic Systems Laboratories; ELISA, enzyme-linked immunosorbent assay; IRMA, 
immunoradiometric assay.
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levels as measured with the second-gen-
eration PTH assays.
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